Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.

The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

NovoCure Limited

Country	Switzerland
Founded	2000
IPO Date	Oct 2, 2015
Industry	Medical Devices
Sector	Healthcare
Employees	1,453
CEO	Ashley Cordova

Contact Details

Address: Neuhofstrasse 21 Baar, 6340 Switzerland
Website	novocure.com

Stock Details

Ticker Symbol	NVCR
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001645113
CUSIP Number	G6674U108
ISIN Number	JE00BYSS4X48
SIC Code	3841

Key Executives

Name	Position
Ashley Cordova	Chief Executive Officer
William F. Doyle	Executive Chairman
Barak Ben Arye	General Counsel
Frank Leonard	Executive Vice President and President of Novocure Oncology
Prof. Yoram Palti M.D., Ph.D.	Founder and Chief Technology Officer
Christoph Brackmann	Chief Financial Officer
Mukund Paravasthu	Chief Operating Officer
Ingrid Goldberg	Vice President of Investor Relations
Michael Puri	Chief Human Resources Officer
Uri Weinberg M.D., Ph.D.	Chief Innovation Officer

Latest SEC Filings

Date	Type	Title
Jan 13, 2025	144	Filing
Jan 13, 2025	8-K	Current Report
Jan 2, 2025	144	Filing
Dec 17, 2024	8-K/A	[Amend] Current report
Dec 2, 2024	8-K	Current Report
Oct 30, 2024	8-K	Current Report
Oct 30, 2024	10-Q	Quarterly Report
Oct 15, 2024	8-K	Current Report
Sep 3, 2024	8-K	Current Report
Aug 2, 2024	UPLOAD	Filing

View All SEC Filings